Paul Biondi, head of strategy and business development at Bristol-Myers Squibb since 2015, left the company last month, according to Endpoints News.
Mr. Biondi reportedly left to become an executive partner at Flagship Pioneering, a company that builds life sciences companies.
The departure was unexpected, as Mr. Biondi was named to be head of strategy and business development for the expanded company once it formally acquires Celgene for $74 billion.
Mr. Biondi had been part of Bristol-Myers Squibb for 17 years and helped the company secure billions of dollars in deals, including a $1.85 billion cancer drug alliance with Nektar Therapeutics, according to Endpoints News.
Read the full article here.
More articles on pharmacy:
House passes Pelosi's drug pricing bill, with a few changes
Walmart agrees to continue accepting paper prescriptions
Sienna Biopharmaceuticals to shut down by end of week